SG11202113075WA - Methods for determining the likelihood of lung cancer - Google Patents
Methods for determining the likelihood of lung cancerInfo
- Publication number
- SG11202113075WA SG11202113075WA SG11202113075WA SG11202113075WA SG11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA SG 11202113075W A SG11202113075W A SG 11202113075WA
- Authority
- SG
- Singapore
- Prior art keywords
- likelihood
- determining
- methods
- lung cancer
- lung
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201905757Q | 2019-06-21 | ||
| PCT/SG2020/050343 WO2020256640A1 (en) | 2019-06-21 | 2020-06-19 | Methods for determining the likelihood of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113075WA true SG11202113075WA (en) | 2021-12-30 |
Family
ID=74040939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113075WA SG11202113075WA (en) | 2019-06-21 | 2020-06-19 | Methods for determining the likelihood of lung cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220397575A1 (en) |
| EP (1) | EP3987292A4 (en) |
| JP (2) | JP7691373B2 (en) |
| CN (1) | CN114026424A (en) |
| SG (1) | SG11202113075WA (en) |
| WO (1) | WO2020256640A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116338191A (en) * | 2023-03-13 | 2023-06-27 | 杭州华然腾创生物科技有限公司 | Lung cancer exosome protein marker based on flow technology and application thereof in aspect of lung cancer screening |
| WO2025028453A1 (en) * | 2023-07-31 | 2025-02-06 | 国立大学法人大阪大学 | Lung cancer biomarker |
| CN120559238A (en) * | 2025-05-27 | 2025-08-29 | 中国人民解放军总医院第一医学中心 | Application of protein markers in the preparation of products for distinguishing benign and malignant ground-glass nodules in the lungs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20040227L (en) * | 2004-02-13 | 2005-08-14 | Jurilab Ltd Oy | A method for detecting the risk of cancer, coronary heart disease and stroke |
| EP2340506B1 (en) * | 2008-09-09 | 2015-11-11 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| WO2012048372A1 (en) * | 2010-10-11 | 2012-04-19 | Medsaic Pty Ltd | Assay for disease detection |
| EP2678448A4 (en) * | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | Circulating biomarkers |
| US20150152474A1 (en) * | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| CA3008272A1 (en) * | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018191560A1 (en) * | 2017-04-12 | 2018-10-18 | Proterixbio, Inc. | Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms |
| WO2018216009A1 (en) * | 2017-05-22 | 2018-11-29 | The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev | Biomarkers for diagnosis of lung cancer |
| CN111971560B (en) * | 2017-12-01 | 2024-06-11 | 康奈尔大学 | Nanoparticles and different exosome subsets for cancer detection and treatment |
| CN110527726A (en) * | 2018-05-25 | 2019-12-03 | 国家纳米科学中心 | The excretion body detection device and application for detecting for non-small cell lung cancer and judging by stages |
-
2020
- 2020-06-19 EP EP20826392.1A patent/EP3987292A4/en active Pending
- 2020-06-19 CN CN202080046013.6A patent/CN114026424A/en active Pending
- 2020-06-19 JP JP2021576097A patent/JP7691373B2/en active Active
- 2020-06-19 US US17/621,407 patent/US20220397575A1/en active Pending
- 2020-06-19 WO PCT/SG2020/050343 patent/WO2020256640A1/en not_active Ceased
- 2020-06-19 SG SG11202113075WA patent/SG11202113075WA/en unknown
-
2025
- 2025-01-06 JP JP2025001853A patent/JP2025061032A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7691373B2 (en) | 2025-06-11 |
| WO2020256640A1 (en) | 2020-12-24 |
| JP2025061032A (en) | 2025-04-10 |
| EP3987292A4 (en) | 2023-10-11 |
| JP2022537820A (en) | 2022-08-30 |
| CN114026424A (en) | 2022-02-08 |
| EP3987292A1 (en) | 2022-04-27 |
| US20220397575A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3443119B8 (en) | Methods for lung cancer detection | |
| IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
| EP3607089A4 (en) | Plasma based protein profiling for early stage lung cancer prognosis | |
| IL292727A (en) | Multispecific antibody | |
| NO20220017A1 (en) | Determining the volume of cuttings | |
| SG11202101397TA (en) | Biomarkers for cancer therapy | |
| GB201919219D0 (en) | Cancer biomarkers | |
| IL276009A (en) | Kits and methods for diagnosing lung cancer | |
| EP4022094A4 (en) | Biomarkers for the diagnosis of lung cancers | |
| HUE054864T2 (en) | In vitro method for the diagnosis of lung cancer | |
| SG11202113075WA (en) | Methods for determining the likelihood of lung cancer | |
| GB201915469D0 (en) | Cancer detection methods | |
| GB201906201D0 (en) | Method for the detection of protate cancer | |
| GB201908591D0 (en) | Methods for cancer diagnosis | |
| GB2580963C (en) | Cancer therapies | |
| SG11202006997SA (en) | A method of determining a risk of cancer | |
| ZA202107946B (en) | Methods for the diagnosis of lung cancer | |
| SI3794148T1 (en) | Methods for the diagnosis of aneurysm or cancer | |
| GB201905861D0 (en) | Methods of detecting cancer | |
| GB201906199D0 (en) | Method for the detection of cancer | |
| GB201911216D0 (en) | Methods of determining the margin of a tumour | |
| GB201910444D0 (en) | Methods of diagnosing cancer | |
| GB201914096D0 (en) | Cancer Biomarker | |
| EP3847282A4 (en) | Biomarkers for cancer therapy | |
| GB201908085D0 (en) | Methods of determining cancer |